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Available online 7 January 2016Background:Middle income countries are facing an epidemic of non-communicable diseases, especially coronary
heart disease (CHD). We used a validated CHD mortality model (IMPACT) to explain recent trends in Tunisia,
Syria, the occupied Palestinian territory (oPt) and Turkey.
Methods: Data on populations, mortality, patient numbers, treatments and risk factor trends from national and
local surveys in each country were collated over two time points (1995–97; 2006–09); integrated and analysed
using the IMPACT model.
Results: Risk factor trends: Smoking prevalencewas high inmen, persisting in Syria but decreasing in Tunisia, oPt
and Turkey. BMI rose by 1–2 kg/m2 and diabetes prevalence increased by 40%–50%. Mean systolic blood pressure
and cholesterol levels increased in Tunisia and Syria.
Mortality trends: Age-standardised CHDmortality rates rose by 20% in Tunisia and 62% in Syria. Much of this in-
crease (79% and 72% respectively) was attributed to adverse trends inmajor risk factors, occurring despite some
improvements in treatment uptake.
CHDmortality rates fell by 17% in oPt and by 25% in Turkey,with risk factor changes accounting for around 46% and
30% of this reduction respectively. Increased uptake of community treatments (drug treatments for chronic angina,
heart failure, hypertension and secondary prevention after a cardiac event) accounted for most of the remainder.
Discussion: CHD death rates are rising in Tunisia and Syria, whilst oPt and Turkey demonstrate clear falls, reﬂecting
improvements in major risk factors with contributions from medical treatments. However, smoking prevalence
remains very high in men; obesity and diabetes levels are rising dramatically.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
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Socio-demographic and economic comparison of the four Eastern Mediterranean coun-
tries.
Sources: Arab HumanDevelopment Report 2009. UNDP, HDR 2007/2008 for Tunisia, Syria
and oPt (data for 2005). Turkey Statistical Institute for Turkish data (2007).
Country
Population
(millions)
Life expectancy
(at birth)
% of total mortality
attributed to CHD
Per capita
GNI PPP$
Tunisia 10.1 74 27.14% 6820
Syria 18.9 75 34.25% 4010
Palestine (oPt) 3.8 72 21.98% 2710*
Turkey 70 74 18.66% 11,330
Footnotes: GNI per capita PPP$ is Gross National Income in PPP US $.
Per capita GNI fromWorld Bank Development Indicators (UN data, 2005).
Life expectancy from World Bank http://www.indexmundi.com/facts/indicators/
SP.DYN.LE00.IN/compare?country=sy.
Proportion of all deaths from CHD http://vizhub.healthdata.org/gbd-compare/ (year 2010).1. Introduction
Coronary heart disease (CHD) is the most common cause of mortal-
ity globally, generating more than 7 million deaths each year. CHD is
expected to remain a leading cause of death beyond2030 [1,2]. Different
regions are at varying stages in their CHD epidemics. For example, after
peaking in the 1960s, CHD mortality in Western countries has subse-
quently halved. Central European countries have experienced more
recent and abrupt declines following socioeconomic transformations
in 1989/1990 [3]. The drivers of these CHD mortality trends are increas-
ingly well characterised in afﬂuent countries. Diverse studies generally
suggested that risk factor improvements explain half to two thirds of
the mortality declines with the remaining one third to half coming from
evidence based treatments [4–6]. CHD and other non-communicable
diseases (NCDs) are increasing as a proportion of total mortality in most
middle and low income countries [1,2,7]. However, much less informa-
tion on the CHD burden (mortality, morbidity and costs) and CHD trends
are available from these populations. This is particularly worrisome for
countries in the EasternMediterraneanRegion,wherepredictions suggest
substantial increases in the number of NCD deaths by 2020 [8]. For
countries in this region, there is therefore an urgent need to analyse
local and regional CHD trends and quantify the impact of risk factors
and treatments.
Risk factor trends across the WHO-EMRO region were recently
summarised in GBD Lancet papers [9–12]. However, such analyses risk
portraying a relatively “homogenous” view of the region, whereas mor-
tality trends are strikingly heterogeneous. For instance, our analyses
show that CHD mortality is rising rapidly in many countries including
Tunisia and Syria, but decreasing in other Mediterranean countries
such as the occupied Palestinian territories and Turkey.
It is clearly important to identify trends in CHDmortality in low and
middle income settings and appraise their variations between coun-
tries, so as to inform effective policies to reduce the future disease bur-
den. Our aim was therefore to analyse recent CHD trends in Tunisia,
Syria, occupied Palestinian territories (oPT, West Bank), and Turkey
(middle income countries in the EasternMediterranean region), and as-
sess the recent contribution of risk factor changes and evidence based
treatments. These four countries were selected on the basis of a) data
availability and quality, b) previous successful collaborations, some of
which had resulted in substantial relevant data collection over time,and c) representing a range of economic development, population
size, and absolutemortality rates across this region (see Tables 1 and 2).
2. Methods
The socio-demographic and economic characteristics of the Tunisian,
Syrian, oPt (West Bank), and Turkish populations are compared in
Table 1.
2.1. The IMPACT model
We used an updated version of the IMPACT CHD mortality model
(Appendix 1). This has been employed and validated in a variety of
countries from North America through Europe to China [4,13]. Data
on risk factor levels and current uptake levels of evidence-based
treatments were identiﬁed by extensive searches for published and un-
published data, and complemented where necessary with speciﬁcally
designed surveys.
Data sources used to populate the model are detailed in Appendix 2
and in previous work [14]. In brief, they include:
a) Population and CHD mortality data (from national statistical
agencies);
Table 2
Crude CHD mortality rates and trends in the four Eastern Mediterranean countries.
Country
(years)
Sex Population
(000)
Number of
deaths
Rate/10
[5]
Number of
deaths
Rate/10
[5]
% change
in rate
% change in directly age-standardised
ratea [annual change %]
Observed increase or
decrease in deathsb
Initial
Year
Final
year
Initial year Final year
Tunisia Total 4301 5700 2106 49 3633 64 +30 +20 [+1.7% p.a.] +682
(1997–2009) Men 2126 2789 1492 70 2429 87 +24 +332
Women 2176 2911 614 28 1205 41 +47 +350
Syria Total 5013 7410 5429 108 12,503 169 +56 +62 [+6.2% p.a.] +6372
(1996–2006) Men 2538 3735 3608 142 8119 217 +53 +3772
Women 2475 3675 1821 73 4384 119 +62 +2660
oPt (1998–2009) Total 610 913 520 85 586 64 −25 −17 [−1.5% p.a.] −122
Men 302 461 318 105 394 86 −19 −60
Women 308 452 202 66 192 43 −35 −62
Turkey (1995–2008) Total 18,932 27,958 79,066 418 96,366 345 −17 −29 [−2.2% p.a.] −35,718
Men 9418 13,655 42,938 456 49,910 366 −20 −17,162
Women 9514 14,303 36,128 379 46,457 324 −14 −18,556
Footnotes:
a CHD mortality rates for ages 35–74 (this age range chosen to be consistently available from all 4 populations), standardised to the World Standard Population.
b This ﬁgure represents the observed change inmortality using indirect standardisation i.e. after accounting for changes in the age-sex structure of the population over time. This is the
change in deaths which the model then attempts to explain. It applies only to the ﬁnal year of the period (2006 in Syria, 2008 in Turkey, 2009 in oPt and Tunisia.
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ments in nine CHD patient groups;
c) Population trends inmajor cardiovascular risk factors (smoking, total
cholesterol, systolic blood pressure, body mass index, diabetes and
physical inactivity).
In order to estimate trends, these data items were acquired for two
time points (referred to as the initial and ﬁnal years respectively).
These were the most recent year with data available (ﬁnal), and one
10–15 years previously (initial); 1997–2009 for Tunisia, 1996–2006
for Syria, 1998–2009 for oPt and 1995–2008 for Turkey). Data were
stratiﬁed by 10-year age groups and sex. Due to variations in data avail-
ability, there were some minor differences in the age groups included
for each population (25+ in Tunisia and Syria; 25–74 in West Bank,
oPt; 35–84 in Turkey).2.2. Change in CHD deaths between the initial and ﬁnal years
The number of CHD deaths expected in the ﬁnal year was calculated
by applying the age and sex speciﬁc death rates in the initial year to the
population age and sex structure in the ﬁnal year. The observed CHD
deaths in the ﬁnal year were then subtracted to estimate the difference
between the initial and ﬁnal years. This was described as the number
of deaths prevented or postponed (DPPs) if negative, or increased
mortality if positive (the number the model attempts to explain in
each country).
Data on patient numbers and treatment uptakes during the initial
and ﬁnal years were obtained for nine mutually exclusive CHD sub-
groups: patients hospitalized during that year for an acute myocardial
infarction (AMI) or unstable angina pectoris (UAP) or heart failure due
to CHD, community-dwelling patients who were post-AMI survivors,
patients with chronic angina, patients receiving revascularisation
(CABG or PCI), patients in the community with heart failure due to
CHD (i.e. those treated outside of hospital), and individuals eligible for
primary prevention beinghypertensive (eligible for blood pressure low-
ering treatments) or having hypercholesterolaemia (eligible for lipid
lowering therapy). These data, along with information on uptake levels
of evidence based treatments were obtained from a combination of
national statistics, local surveys, grey literature, hospital records and
speciﬁcally designed surveys as appropriate (Appendix 2). These were
used for estimating treatment coverage in the initial and ﬁnal years.
Data on trends in population risk factors (smoking prevalence, total
cholesterol, systolic blood pressure, body mass index, diabetes) wereobtained mainly from national and local surveys complemented by
published and grey literature (Appendix 2).2.3. The mortality changes attributed to risk factor trends
The deaths attributable to population changes in risk factor levels
were estimated using one of two approaches.
The regression β coefﬁcient approachwas used to quantify the popu-
lation mortality impact of change in continuous risk factors (systolic
blood pressure, total cholesterol and BMI). The mortality change was
then estimated as the product of the CHD deaths observed in the initial
year, the subsequent change in the risk factor, and the β regression
coefﬁcient quantifying the change in CHD mortality expected per unit
of absolute change in the risk factor (Appendix 1). These regression
coefﬁcients were derived from international studies after controlling
for all other coefﬁcients included in the model (see Appendix 1,
eTable3). For example, the coefﬁcient for BMI is independent of that
for BP, cholesterol and Diabetes. They also control for the effects of in-
creased treatment uptake (for lowering blood pressure and cholesterol
levels) over time (see Appendix 1, page 7).
A second approach, population attributable risk fraction, was used for
categorical variables — smoking, diabetes, and physical inactivity by
applying Levin's formula (Appendix 1).
Lag times between the change in cardiovascular risk factor levels and
change in CHD mortality rates were assumed to be relatively rapid
[15–18] and were therefore not speciﬁcally modelled.
CHD deaths are caused bymultiple risk factors acting simultaneous-
ly. Enumeratingmortality changes from risk factor trends should ideally
therefore not use a simple additive approach. Instead, the effects of risk
factor changes were jointly estimated using the cumulative risk-
reduction approach (a multiplicative approach). This can be stated in
the equation:
Cumulativeeffect=1−((1−a)∗(1−b)∗(1−c)∗ ...(1−n))
where n is the total number of additional risk factors (in this case 5 as in
total we modelled 6).
This cumulative effect of change in all risk factors over the study
period was calculated by age and sex for each country (see Appendix 1,
pages 8–10). The ratio of the cumulative effect to the corresponding ad-
ditive effect was then calculated, yielding 70 adjustment factors. These
adjustment factors were used to scale down the additive DPPs for each
risk factor. These adjusted DPPs, summed over all seven risk factors,
then equalled the estimated total combined DPPs, capturing the
153J. Critchley et al. / International Journal of Cardiology 208 (2016) 150–161multiplicative net impact of positive and adverse changes in risk factors.
All risk factor DPPs quoted in the results tables refer to the adjustedDPPs.2.4. Estimating the mortality reduction attributable to medical and surgical
treatments
The model included all medical and surgical treatments for the nine
mutually exclusive patient groups in both the initial and ﬁnal years.
Case-fatality datawere obtained from large, unselected, population-
based patient cohorts. Survival beneﬁt over a one-year time interval
was used for all treatments, as we are only interested in quantifying
deaths prevented or postponed for at least one year. (Appendix 1)
The mortality reduction for each treatment was then calculated as
the number of patients in each group, multiplied by the group age-
sex-speciﬁc case fatality, the treatment uptake and the relative mortal-
ity reduction (efﬁcacy). The efﬁcacy of each therapeutic interventionwas
based on recent meta-analyses and randomised controlled trials
(Appendix 1, eTable 1).
The potential effect of multiple treatments in an individual patient
was calculated conventionally using the Mant and Hicks cumulative
relative beneﬁt approach [3].2.5. Treatment adherence and overlaps (Appendix 1, page 7)
To avoid double counting, potential overlaps between different
groups of patientswere identiﬁed and adjusted. Adherence (thepropor-
tion of treated patients actually taking therapeutically effective levels of
medication) was assumed to be 100% in hospital patients, 70% in
symptomatic community patients, and 50% in asymptomatic community
patients [19–21].Table 3
Risk factor trends and consequent mortality changes in the four Eastern Mediterranean countr
Country Risk factor Prevalence Absolu
Initial year Final year
Tunisia (1997–2009) Smoking 23.9 22.7 −1.2
SBP (mmHg) 130.4 131.0 +0.60
Cholesterol (mmol/l) 4.59 4.73 +0.14
BMI (kg/m2) 26.0 27.5 +1.44
Diabetes % 12.1 17.3 +5.2
Physical inactivity% 98 85 −13
Total
Syria (1996–2006) Smoking 33 37 +4
SBP (systolic BP) 122.2 130.9 +8.7
Cholesterol 5.05 5.34 +0.29
BMI 28.0 29.7 +1.8
Diabetes 9 13 +4
Physical inactivity% − − −
Total
oPt (West Bank) (1998–2009) Smoking 32% 22% −10
SBP (systolic BP) 121.4 121.3 −0.10
Cholesterol 5.0 4.94 −0.06
BMI 28.0 31.0 +3
Diabetes % 9 12 +3
Physical inactivity% 84 92 +8
Total
Turkey (1995–2008) Smoking% 27 16 −11
SBP 127.2 124.6 −2.6
Cholesterol 4.96 4.97 +0.01
BMI 27.4 29.0 +1.6
Diabetes % 15.5 18.7 +3.2
Physical inactivity% 70 65 −5
Total
⁎ Footnote: A positive value denotes an increase in the risk factor and an increase in deaths att
a consequent decrease in deaths attributed to the risk factor. Physical activity data not availabl2.6. Sensitivity analyses (Appendix 1, page 7)
Similar to economic evaluation studies in health [22], 95% uncertain-
ty intervals around the model output (i.e., DPPs) were calculated using
Monte Carlo simulation. This calculation involved replacing all ﬁxed
input parameters used in themodel by appropriate probability distribu-
tions, and repeatedly recalculating the model output with values sam-
pled from the deﬁned input distributions (see Appendix 1 page 10
eTable 1). We used the EXCEL add-in Ersatz software (www.epigear.
com) to perform10,000 runs to determine the 95%uncertainty intervals
of the DPPs (2.5th and 97.5th percentile values corresponding to the
lower and upper limits). For clarity, the “best” estimates only are report-
ed in the text and the “maximum” and “minimums” in Tables 3, 4a and
4b.
2.7. Model validation: comparison with observed mortality falls
Themodel estimates for the total number of deaths prevented or in-
creased by each risk factor change and each treatment were summed.
These estimates were then compared with the observed changes in
mortality in each age group for men and women.
3. Results
3.1. Mortality trends
Age adjusted CHDmortality rates rose by 20% in Tunisia and by 62%
in Syria during the observation period for each country. In contrast, age
adjusted CHD mortality rates fell by 17% in oPt and by 29% in Turkey
(Table 2, Fig. 1).
These mortality trends resulted in approximately 680 additional
deaths in Tunisia and some 6370 additional deaths in Syria, in theies (men & women combined).
te change in risk factor⁎ Changes in deaths
(increases or decreases)⁎
% of total mortality trend
Estimated Min Max
−14 −53 24 −2.1
+166 +20 +350 +24.3
+273 +204 +384 +40.0
+86 +60 +112 +12.6
+62 +4 +123 +9.2
−35 −48 −23 −5.1
+538 +368 +777 +78.9%
+171 −216 +549 +2.7
+2073 +1209 +3576 +32.5
+1348 +1006 +1508 +21.2
+373 +266 +479 +5.9
+636 +242 +1013 +10.0
− − − −
+4601 +3428 +6186 +72.2%
−29 −78 +11 −23.7
−33 −235 155 −27.3
−39 −140 46 −32.3
+2 −23 +28 +1.7
+28 −16 +71 +22.7
+16 +8 +17 +10
−56 −160 +294 −45.7%
−8423 −10205 −6679 −23.6
−8723 −12453 −4763 −24.4
+310 −2238 +2797 +0.9
+3310 +2783 +3878 +9.3
+4456 +2236 +6651 +12.5
−1683 −2418 −1085 −4.7
−10763 −16191 −4955 −30.1%
ributed to the risk factor increase. A negative value denotes a decrease in the risk factor and
e from Syria. Individual rows may not sum to their sub-totals due to rounding.
Table 4a
Treatment contributions: numbers of patients in speciﬁc groups and CHD deaths prevented or postponed in Tunisia and Syria where CHD mortality was rising (men and women
combined).
Country Treatment group Eligible patients Deaths prevented or postponed
(estimates)
Estimated % reduction in CHD
mortality attributed to treatments
Best (Min) (Max) Best (Min) (Max)
Tunisia Acute myocardial infarction (AMI) 4505 89 78 101 7.8 6.9 8.9
Unstable angina 6755 77 67 88 6.8 5.9 7.8
Secondary prev post AMI 24058 95 87 103 8.4 7.7 9.1
Secondary prev post CABG/PCI 1300 3 2 3 0.3 0.2 0.3
Chronic angina 53436 0 −19 15 0.0 −1.7 1.3
Hospital heart failure 3614 37 22 55 3.3 2.0 4.9
Community heart failure 25298 49 43 55 4.3 3.8 4.9
Hypertension treatment 1496744 80 38 138 7.1 3.4 12.2
Statins primary prevention 601743 21 18 24 1.9 1.6 2.1
Totala 448 376 530 39.7 33.2 46.9
Syria Acute myocardial infarction (AMI) 18002 287 250 321 3.4 2.9 3.8
Unstable angina 22877 150 142 158 1.8 1.7 1.9
Secondary prev post AMI 78976 372 280 481 4.4 3.3 5.7
Secondary prev post CABG/PCI 26316 65 46 84 0.8 0.5 1.0
Chronic angina 319974 803 638 1013 9.4 7.5 11.9
Hospital heart failure 6927 84 −9 168 1.0 −0.1 2.0
Community heart failure 52251 332 279 376 3.9 3.3 4.4
Hypertension treatment 863425 45 17 78 0.5 0.2 0.9
Statins primary prevention 307295 6 4 10 0.1 0.0 0.1
Totala 2145 1648 3170 25.2 23.0 27.4
The denominator is the estimated total number of CHD deaths in the absence of any treatments i.e. Tunisia 1130 (680 + 450) and Syria 8515 (6370 + 2145).
For Tunisia, chronic angina treatment in the community (best estimate) is zero since aspirin usewas already high in themodel base year (1997), and hence therewas little scope for increase
over time.
KEY:
AMI = acute myocardial infarction.
CABG= coronary artery bypass graft surgery.
PCI = Percutaneous intervention.
a The totals row does not represent the sum of each treatment component due to the bootstrap methodology.
154 J. Critchley et al. / International Journal of Cardiology 208 (2016) 150–161ﬁnal year comparedwith the initial year. The declines in mortality rates
resulted in approximately 120 fewer deaths in oPt and 35,720 fewer
deaths in Turkey (see Table 2; minimum and maximum estimates are
detailed in Tables 3 and 4a and 4b.
Large variations in CHD mortality trends were seen for men and
women, with the relative changes generally favouring men, except in
Tunisia (Table 2, Figs. 2–3).Table 4b
Treatment contributions: numbers of patients in speciﬁc groups and CHD deaths prevented
combined).
Country Treatment group Eligible patients D
(
B
oPt Acute myocardial infarction (AMI) 489
Unstable angina 489
Secondary prev post AMI 2266
Secondary prev post CABG/PCI 1974
Chronic Angina*** 22180
Hospital heart failure 468
Community heart failure 2342
Hypertension treatment 81894
Statins primary prevention 7030
Total
Turkey Acute myocardial infarction (AMI) 91317
Unstable angina 45658
Secondary prev post AMI 759071
Secondary prev post CABG/PCI 273379
Chronic angina*** 103293
Hospital heart failure 46511
Community heart failure 424511
Hypertension treatment 10553133
Statins primary prevention 4483287
Total 1
KEY:
AMI = acute myocardial infarction.
CABG= coronary artery bypass graft surgery.
PCI = percutaneous intervention.3.2. Risk factor trends and associated mortality changes (Fig. 2 and Table 3)
3.2.1. Smoking
Smoking prevalence decreased in all countries apart from Syria.
Major changes were seen in Turkey; a fall of−11% (41% relative reduc-
tion) followed by oPt−10% (31% relative reduction). However smoking
generally remained common amongmen (45% to 59%prevalence acrossof postponed in the oPt and Turkey where CHD mortality was falling (men and women
eaths prevented or postponed
estimates)
% of the mortality change explained
est (Min) (Max) Best (Min) (Max)
2 2 2 1.9 1.3 1.7
1 1 1 1.1 1.0 1.2
8 6 10 7.3 5.0 8.6
2 2 3 1.9 1.5 1.9
10 9 11 8.4 7.2 8.8
2 2 3 1.5 1.5 2.1
7 5 8 5.3 4.5 6.2
5 4 6 4.1 3.1 6.2
0 0 0 0 0 0.0
38 29 46 31.5 23.4 37.7
1677 1448 1930 4.7 4.1 5.4
638 562 722 1.8 1.6 2.0
4570 4100 5088 12.8 11.5 14.2
1752 1401 2160 4.9 3.9 6.0
2622 2046 3265 7.3 5.7 9.1
1025 891 1144 2.8 2.5 3.2
2338 2074 2632 6.5 5.8 7.4
2153 1899 2427 6.0 5.3 6.8
41 32 53 0.1 0.1 0.1
6794 16026 17598 47.0 44.9 49.3
Fig. 1. Age-standardised CHD mortality rates and trends in the four Eastern Mediterranean countries (initial year and ﬁnal year)*.
155J. Critchley et al. / International Journal of Cardiology 208 (2016) 150–161the four countries). In Tunisian women, smoking prevalence doubled
from 2% to 4%, resulting in some 30 additional deaths in the ﬁnal
model year. In Syria, smoking increased inwomen from 10% to 15% gen-
erating approximately 100 additional deaths in the ﬁnal year. In oPt
smoking prevalence decreased by 14% among men and by 7% in
women. In Turkey, there was a major reduction in smoking prevalence
of 20% in men and 2% in women, accounting for over 7200 fewer CHD
deaths in men and nearly 1200 fewer deaths in women (Table 3 and
Appendix 3).
3.2.2. Systolic blood pressure
Population mean systolic blood pressure (SBP) levels increased
slightly in Tunisia (+0.6 mm Hg) and rose substantially in Syria
(+8.7 mm Hg) but were broadly static in oPt and decreased in Turkey
(−2.6 mm Hg).Fig. 2. Proportion of deaths (increasing or decreasing) attribuImportant differences were seen between men and women. In
Tunisia, SBP increased on average by 4 mm Hg for men (129 mm Hg
to 133 mm Hg), whereas in women it fell by 2 mm Hg (131 mm Hg to
129 mm Hg) — see Figures and Appendix 3. Similarly in oPt, average
SBP decreased by 0.7 mm Hg in men while among women it increased
by 0.7 mm Hg.
The increase in SBP in Tunisia and Syria resulted in over 2200
additional deaths according to our model estimates. The decrease in
Turkey and oPt resulted in nearly 9000 CHD fewer deaths in the two
countries.
3.2.3. Cholesterol
Cholesterol levels increased in both Syria (+0.3mmol/l) and Tunisia
(+0.14 mmol/l). In Turkey levels remained broadly constant
(+0.01 mmol/l), and in oPt decreased by 0.06 mmol/l.ted to changes in major risk factors, (by country and sex).
Fig. 3. Proportion of deaths prevented or postponed attributable to increased uptake of speciﬁc treatments (by country and sex).
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terol increased by 0.73 mmol/l in men but decreased by 0.42 mmol/l in
women. In Syria, cholesterol levels increased in both men and women
(0.22 and 0.38 mmol/l respectively), and rose modestly in Turkey (by
0.01 mmol/l in men and women). In oPt, cholesterol levels decreased
in men (−0.07 mmol/l) and women (−0.11 mmol/l). Over 270
additional CHD deaths in Tunisia, 310 in Turkey and 1350 in Syria were
attributable to the rises in cholesterol. The reduction in oPt resulted in
approximately 40 fewer CHD deaths.3.2.4. BMI
BMI rose substantially in all four countries, increases ranging from
1.4 kg/m2 in Tunisia to 3 kg/m2 in oPt. Absolute levelsweremuchhigher
in women over the whole time period. BMI generally rose more among
men than women (except in Syria where the increase was similar in
men and women). More than 80 deaths in Tunisia, nearly 400 deaths
in Syria, and over 3000 deaths in Turkey were attributed to this obesity
rise (Table 3).3.2.5. Diabetes
Diabetes prevalence also increased substantially in all four countries.
Overall, a 43% relative increase was observed in Tunisia, 52% in Syria,
44% in oPt and 21% in Turkey. In general bigger increases were seen in
men than in women. In Tunisia, diabetes prevalence increased more
among men (12% to 19%) compared with women (12% to 16%). In
Syria there was a similar relative increase in diabetes in men and
women of +52%, but overall prevalence was higher in women (15%
versus 11% in men). In oPt, the relative increases in diabetes were also
around 2.5 times as much in men (+64%) as in women (+26%), In
Turkey diabetes increased similar in men and women (+21%).
Ourmodel estimated that over 5000 additional CHD deaths could be
attributed statistically to the rising diabetes prevalence in the region
(approximately 30 in oPt, 60 in Tunisia, 600 in Syria, and around 4500
additional deaths in Turkey — Table 3).3.2.6. Physical inactivity
Trends in physical inactivity are particularly difﬁcult to interpret and
could not be estimated at all in Syria. The contribution of physical
inactivity trends was in general small because available data suggested
that physical activity levels were low and remained low over the time
period of the study.
3.3. Effect of adjusting for cumulative risk factor trends
Adjusting for multiple risk factor trends occurring simultaneously
reduced the proportion of the total mortality change that could be
explained by risk factors signiﬁcantly. In absolute terms, this was re-
duced by between 6 percentage points in Turkey (from 36% to 30%);
10 in oPt (from 56% to 46%) to 18 in Syria (from 90% to 72%) and 19 per-
centage points in Tunisia (from 98% to 79%) to and age group, compared
with a simpler additive model.
3.4. Estimating the contribution of medical and surgical treatments
The impact of other primary preventive therapies (mainly statins)
was low except in Tunisia (Table 4a, Fig. 3).
3.5. Overall contribution of evidence based treatments and risk factors
Overall treatment uptakes increased in all countries.
a) in countries with increasingmortality rates (Tables 3 & 4a)
Adverse trends in risk factors explained approximately 79% of the
observed mortality rise in Tunisia and over 72% of the increase in
Syria, after adjusting for the effects of cumulative risk factor changes.
In effect, this means that between 21% of the rise in Tunisia and 28%
in Syrian cannot be explained.
These mortality rises occurred in spite of improved treatment
uptakes, resulting in approximately 450 fewer CHD deaths in
Tunisia and some 2140 fewer deaths in Syria (Table 4a).
b) in countries with decliningmortality rates (Tables 3 & 4b)
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plained more than 46% of the overall mortality fall with treatments
accounting for approximately 32% and in Turkey the relative contri-
bution was approximately 30% for risk factor reduction and 47% for
increased treatment uptake (Table 3). This means that 22% of the
decline was not explained in Turkey and 23% in oPt.
The largest medical contributions generally came from the commu-
nity based treatments (treatment outside of hospital settings), par-
ticularly prescribing of aspirin and other secondary preventive
medical therapies such as statins and anti-hypertensives after AMI,
and community treatments for heart failure. In oPt and Turkey,
hypertensive therapies also made important contributions.
3.6. Model validation
The IMPACT model has been replicated in over 15 countries world-
wide, though most of these are high income countries. The model has
also recently been validated for forward prediction in European popula-
tions [23]. The agreement for future projection was generally high
(varying from 90% of 106% of expected deaths prevented or postponed,
albeit over short periods of time [23,24]. We assessed agreement
between model estimates of the number of deaths prevented or post-
poned with ofﬁcial mortality statistics in these countries. The IMPACT
Model estimates were apparently able to explain approximately 75%
of the observed mortality changes in Turkey, and oPt, but less in Syria,
and Tunisia respectively, although the ﬁt depends on whether adjusted
or unadjusted risk factor DPPs are combined, and whether risk factor
and treatment trends are also summed (Tables 3, 4a and 4b, Appendix
4 Table 2). This may reﬂect that the model was originally developed
for populations where CHD mortality is declining, or possibly reﬂect
issues with data quality. However the model does not include trends
in all CHD risk factors and hence 100% agreement would not be
expected.
4. Discussion
4.1. Summary of main ﬁndings
CHDmortality rates have dramatically risen in Tunisia and Syria, but
have thankfully fallen in the occupied Palestinian territory (oPt) and
Turkey. These mortality trends mainly reﬂect changes in major cardio-
vascular risk factors, moderately alleviated by treatment contributions.
These treatment contributions appeared slightly greater in Tunisia and
Turkey; this may reﬂect a stronger primary health care system in the
latter case [25], and higher uptake of effectivemedical therapies for sec-
ondary prevention after AMI or CABG/PCI surgery. In Tunisia, uptake of
initial treatments for AMI was also proportionately higher. Treatment
contributions appeared weakest in Syria, probably reﬂecting a limited
and deteriorating primary health care system (even before 2011) [25],
though there was some prescribing of effective drug treatments for
chronic angina and heath failure. In all four countries, BMI and hence
diabetes was rising, and these adverse trends would have resulted in
increases in CHD mortality of about 2–10% and 10–20% respectively.
However, trends in other risk factors were more heterogeneous. In
Syria, smoking prevalence increased slightly (explaining 3% of the up-
ward trend) but in Turkey and oPt smoking prevalence fell substantially
(explaining almost 25% of the reduction in mortality). Systolic blood
pressure also fell in Turkey (explaining almost another 25% of the
downward trend), possibly reﬂecting both increased prescribing of
anti-hypertensives and falls in salt consumption [26,27]. Cholesterol
levels declined slightly in oPt and were relatively ﬂat in Tukey, but
around 40% of the small increase in CHD mortality in Tunisia could be
attributed statistically to rising cholesterol levels, and just over 20% in
Syria. Overall, in the two countries with increases in CHD mortality,(Tunisia and Syria), the adverse risk factor trends explained most
(70–80% roughly) of the increase. In populations with falling CHDmor-
tality rates, about one-third to half the declinewas attributed to declines
in major risk factors (smoking cholesterol and blood pressure), with
another one-third to half attributed to increased uptake of effective
medical and surgical treatments for CHD (see Appendix 4, Table 2). In
some Western countries, the IMPACT model has been able to explain
more of the mortality trends, but this may not be surprising given
imperfect data. The data on risk factor changes generally came from
high quality nationally representative studies using good valid mea-
surement methods such as repeated BP measurements, fasting plasma
glucose for diabetes, particularly in Tunisia. However in Syria and oPt
some data was based on sub-regional studies which we had to assume
were nationally representative, particularly at the earlier time point.
Risk factor data and quality are addressed in more detail in another
publication [14] and Appendix 3. Routine data on treatment uptakes
and trends was of more variable quality but we supplemented this by
carrying out our own surveys and audits speciﬁcally for this project
(see Appendix 2). It is possible that our analyses may slightly over-
estimate the treatment contributions, since hospitals that take part in
such studies are more likely to be tertiary referral centres, and may
hence be performing better than other secondary centres, although
we adjust for this factor in probabilistic sensitivity analyses. We would
also acknowledge that treatment data from the ﬁrst time point (in the
mid-1990s) were more uncertain and limited. However, this does not
greatly inﬂuencemodel estimates since very little in theway of effective
medical or surgical treatments were available in any of the 4 popula-
tions at the beginning of the model period. Death certiﬁcation data is
more variable in quality in low and middle income countries. Reassur-
ingly, there has been no change in completeness of Tunisian death
certiﬁcation over this time period which could bias our results [28],
and death certiﬁcation data from oPt was classed as “medium” quality
according to WHO criteria [29]. In Turkey, analyses of causes of death
from a previous national burden of disease study were used to adjust
death certiﬁcation estimates [30]. Whilst there are concerns about
national death registry deaths in Syria, we used alternative sources
(the Aleppo Household survey) [31], which we considered more valid
albeit at the possible cost of generalisability.The diverging trends pow-
erfully emphasise that regions should not be treated homogeneously
[32]. Previous Global Burden of Disease analyses [33] projected speciﬁc
risk factor trends against the levels and changes inwealth and urbanisa-
tion in around 100 developing countries. For example, with increasing
afﬂuence both obesity and cholesterol levels tend to increase. Our
study shows that CHD death rates are rising in Tunisia and even more
substantially in Syria (prior to the current conﬂict), the poorest of the
four countries (GrossNational Income in International Dollars (Purchas-
ing Power Parity) GNI I$ 4010 in 2005, and compared with Tunisia (GNI
6820). By contrast, Turkey, with a far higher GNI of 11,330 demonstrat-
ed clear mortality falls. Furthermore, all four populations experienced
substantial increases in BMI, with Syria showing the greatest increase,
and Turkey the least.
The occupied Palestinian territory (oPt) appears an interesting
outlier, with slight cholesterol falls (and generally favourable risk
factor trends) despite apparently very modest levels of wealth and the
lowest GNI of the four (GNI I$2710). However, there are known difﬁcul-
ties in estimating GNI for the oPt [34]. The mortality falls may reﬂect
substantial international donations, high levels of education and literacy
and a relatively well developed public health system [35,36], partly
facilitated by a small population size. Furthermore, it suggests that
CHDmortality trends cannot simply be predicted by levels of economic
development.
Perhaps most critical in explaining differences across the region are
the smoking levels and trends. Smoking prevalence remained very high
in men in Syria and Tunisia but declined in Turkey and oPt. Although
smoking is relatively uncommon among women in Tunisia and Syria,
both may be underreported (particularly as most national sources are
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ing, particularly in younger people [37].
Different trends were seen for obesity between men and women.
Although greater increases in BMI were observed in men, mean BMI
remains much higher in women, particularly in Syria and Tunisia. The
high levels of female obesity presumably reﬂect traditional gender
roles, gender inequality, and limited opportunities for women to leave
the home environment (and partake in any physical activity). Data on
physical activity are seriously limited across the region; however a
recent Tunisian survey [38] demonstrated very low levels of female
participation in regular exercise of any kind. Trends in other risk factors
were broadly similar by gender.
4.2. Dietary trends
Rapid risk factor andmortality changes observed in this study clearly
reﬂect substantial economic and nutritional transitions in the Middle
East. A dramatic rise in per capita energy and fat supplies in most coun-
tries has occurred over the past four decades. For example, between
1971 and 1997, calorie intakes rose by over 40% in Syria and Tunisia,
(from 2340 to 3350 cal in Syria and from 2280 to 3280 cal in Tunisia)
[39]. Fat intakes similarly increased by over 60% over the same time
period [39]. Sugar consumption may also have risen [39–41], whilst
intakes of fruit, vegetables and ﬁbre have all fallen [39]. The high calorie
intakes, and limited physical activity have resulted in particularly high
obesity rates, and hence escalating diabetes prevalence in this region.
Sodium intake is also high, thereby increasing blood pressure [26].
Rapidly increasing urbanisation probably underlies some of the dietary
trends, with increased availability of processed foods, and possibly
compounded by lower requirements for routine physical activity. In
Turkey for example, between 1988 and 2008 the proportion of the
population dwelling in urban areas increased from 25% to 75%.
4.3. Methodological adjustment for cumulative risk factor trends
The methodological reﬁnement in this paper, accounting for multi-
ple risk factor trends occurring simultaneously, signiﬁcantly affected
the proportion of themortality trend that could be attributed to individ-
ual risk factor changes, reducing it by up to nearly 20% compared with
previous analyses. This contrasts with a previous study which did not
demonstrate signiﬁcant differences between these two approaches in
a UK setting [34]. This difference may reﬂect the rapid risk factor trends
that have been observed in the middle income countries in this study,
and suggests that this reﬁnement is most critical in countries in transi-
tion, undergoing rapid epidemiological changes. However,most current
global modelling studies that attribute mortality trends to speciﬁc risk
factor trends do not generally use a cumulative approach. Our study
thus provides evidence of the importance of speciﬁc modelling
approaches in this context, as well as original data for this under-
researched region.
4.4. Increasing uptake of evidence-based treatments
Some favourable trends in the uptake of effective treatments have
occurred, particularly in oPt and Turkey. The major contributors were
improved uptake of aspirin and other secondary prevention medica-
tions, plus community heart failure treatments. Although the patterns
were broadly similar there were some important differences between
countries. For instance Tunisia had a much higher uptake of statins for
primary prevention, but in other populations these uptakes remained
low at the end of our period of analysis (approximately 2008), suggest-
ing signiﬁcantly greater potential with increasing use in the future [42].
Simple, accepted drug regimens or combinations (generally including
aspirin, a calcium channel blocker, ACE inhibitor and statin) may be
cost-effective for CHD patients even in low income settings and merit
further study [43,44]. However, treatment uptakes are still generallyvery low [45] emphasising the remaining potential for cheap, effective
medical therapies to help reduce CHD mortality rates.4.5. Strengths and limitations of the data and IMPACT model methodology
Modelling studies have a number of potential strengths, providing
integration and simultaneous consideration of large amounts of data.
The IMPACT Model has been widely used to explain CHD mortality
trends, and has now been validated in over 15 high income populations
[34]. However, this is the ﬁrst analysis of middle income populations in
the Middle East.
We acknowledgemany limitations. Allmodels are dependent on the
quality and extent of data available, and the outcome data (CHDmortal-
ity) is particularly important. Mortality trends by cause of death remain
uncertain in many low and middle income countries due to incomplete
or inaccurate coding, and a lack of trend data. Global Burden of disease
analyses highlight the signiﬁcant declines in adult mortality seen in
many low and middle income countries in recent decades [46]. Life
expectancy has risen in all 4 populations, but this is driven mainly by
substantial declines in infant mortality [47]. As CHD is a major compo-
nent of total mortality, this might lead us to expect that age-speciﬁc
CHD mortality is also falling globally. However, our data from Syria
and Tunisia demonstrated increasing age-speciﬁc CHD mortality in re-
cent years. In support of our ﬁndings, major CHD risk factors (smoking,
blood pressure, and blood cholesterol) which together account for
about 85% of variation in CHD mortality [48] were either stagnant or
increased in Syria and Tunisia over this time period; no substantial
decreases were observed. Reassuringly, there has been no change in
completeness of Tunisian death certiﬁcation over this time period
which could bias our results [28], and whilst there are concerns about
national death registry deaths in Syria, we used alternative sources
(WHO and the Aleppo Household survey). A picture of continued
adult mortality decline is by no means clear cut since other authors
using the Demographic and Health surveys suggest that mortality de-
cline has recently ﬂattened in some MENA countries (Jordan, Yemen
and Morrocco) [49]. Further, an increases in age-speciﬁc CHDmortality
has also recently been reported in the largest country in this region
(Egypt [46]). Hence our detailed analyses by country highlight the het-
erogeneity in cause of death trends among middle income countries.
The Middle East suffers particularly high male smoking rates and very
low levels of physical activity; BMI and diabetes have been increasing
faster than elsewhere in the world.
Overall, the IMPACT model apparently explained up to 77% of the
mortality trend observed in each country. This appears acceptable,
particularly considering the variable death certiﬁcation and imperfect
risk factor measurement across the region.
The model itself makes many simplifying assumptions. First it
ignores potential lag times between changes in a risk factor and change
in mortality, however, evidence suggests that lag times can be very
short in practice [15–18]. It assumes a log-linear association between
risk factors and CHD mortality; and the regression approach implicitly
assumes that other, unmeasured risk factors have not changed over
the model time period. This is not likely to be the case in practice. It as-
sumes that trial estimates (efﬁcacy) of medical and surgical treatments
can be realised in practice; however, it does account for variable uptake
and compliance of treatments. Estimates of one-year case-fatality had to
be obtained from international rather than national sources and are
thus uncertain (see eTable 3). We did not explicitly consider competing
risks. However, reductions in smoking prevalence (in Turkey and oPt)
should also reduce death rates from common cancers and respiratory
diseases. Increases in BMI and diabetes however might also increase
risk of deaths from diabetes or cancers. The model does account for
changes in age structure over time, which are small over this relatively
short time period. The data itself are only available at the population
level. The model itself is thus essentially ecological in nature. However,
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evidence of a causal relationship with CHD mortality.
Naturally, data availability was variable across the countries
involved. We populated the models with “national level” data or data
from surveys covering a range of representative areas (such as in
Turkey). Most of the major risk factors were measured rather than
self-reported e.g. BMI was measured as height and weight, SBP and
total cholesterol and diabetes were also measured using appropriate
blood pressure monitors and blood tests. Smoking status is usually
self-reported in surveys.While generally considered valid, this could re-
sult in an underestimate of smoking status, particularly among women
in countries like Tunisia, where female smoking is still culturally
frowned upon [50]. Physical inactivity is also self-reported, and could
be less reliable. Using national level or regional data may also conceal
important heterogeneity within countries e.g. by urban/rural location
or socio-economic status [30,31,51–53]. It is possible that the relative
contribution to CHD mortality trends from increased treatment uptake
could be lower in some poorer, rural regions where health insurance
coverage is lower and servicesweaker. For example, situational analyses
of NCD clinics, a separate part of this EC funded project, found that both
patient record keeping and staff skillswereweaker in poorer rural areas,
and alongwith inadequate referral arrangements, could potentially lead
to poorer treatment outcomes [25].
Our model explains change in mortality over time, rather than the
absolute levels. Whilst trends within the four countries are considered
reliable (Appendix 2), comparisons between them should be made
cautiously, due to potential differences in coding practices and quality
of death certiﬁcation. The model probably captures all major contribu-
tions to mortality change, but the contributions of each component
have substantial uncertainty. However, probabilistic sensitivity analysis
demonstrated that the relative contributions of risk factor changes and
treatments to the overall mortality trends were reasonably consistent.
The current model only reports on mortality. Other outcomes
(incidence, life years gained or lost, and cost-effectiveness) though
potentially valuable [54]would require further datawhich is not readily
available in the region. However this merits attention in future work.
4.6. Policy implications
Our results may be cautiously generalisable to other low andmiddle
income populations, especially in the Eastern Mediterranean region
(recognising the many potential similarities in social, cultural and
economic attributes of these societies). It also highlights both the chal-
lenges (missing data) and beneﬁts (identifying potential heterogeneity
and effects of individual treatments) of grounding analysis in country-
speciﬁc data, compared with other approaches. Clearly, the political
catastrophe that has engulfed Syria since 2011 inevitably reduces the
immediate relevance of the lessons that may be drawn from our
Syrian ﬁndings; however, in the longer term these may provide a
baseline for subsequent policy analysis and future policy development
in a post-conﬂict era.
Our ﬁndings highlight the consistently powerful effects of even
small changes in the major cardiovascular risk factors, smoking, blood
pressure and cholesterol. Furthermore, dramatic rises in diabetes have
occurred across the region, mainly reﬂecting marked increases in BMI
and adverse trends in diet (particularly salt, sugar, saturated fat and
calorie intakes). These dietary and obesity trends also underlie most of
the observed increases in blood pressure and cholesterol levels.
These current adverse risk factor trends are very worrying and
represent a clear wake-up call. They justify stronger regional and global
policy responses targeting smoking, unhealthy diet, and physical
inactivity. Effective interventions exist [55,56,57–59]; but their imple-
mentation may be politically challenging across diverse cultures.
However, our analysis clearly demonstrates different trends across the
countries, suggesting that national policies should perhaps be tailored
to local priorities. Countries such as oPt and Turkey have performedrelatively well on reducing SBP, cholesterol and smoking (despite
on-going political difﬁculties). Neighbouring countries might therefore
perhaps consider similar policies. Mortality trends broadly reﬂect chang-
es in risk factors more than improved treatment uptake. In countries
with well-established primary health care systems, medications may
provide a useful strategy in addition to population-based interventions.
Yet, whilst appropriately targeted medical interventions can be cost-
effective, they may be difﬁcult to implement, especially in countries
without comprehensive primary health care. Population based policy in-
terventions to reduce risk factors can also be challenging to implement
and enforce, and the evidence base for reducing obesity and diabetes in
low and middle income countries is sparse. However, evidence from
other countries suggests that tobacco control and dietary policies can
be powerful, rapid and cost saving [55,56,60,61,62]. These evidence-
based policy interventions should therefore be strongly recommended
for the prevention of both CHD and other non-communicable diseases.
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